Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD
NCT02411474 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21
Last updated 2015-04-08
Summary
Investigate the profiles of tear cytokines in patients who underwent stem cell transplantation (SCT) and attempted to determine the applicability of tear cytokines in the diagnosis of chronic graft-versus-host disease (GVHD). Evaluate tear cytokines as biomarkers of chronic ocular GVHD severity.
Conditions
- Chronic Graft-versus-host Disease
Sponsors & Collaborators
-
Yonsei University
lead OTHER
Eligibility
- Min Age
- 20 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-03-31
- Primary Completion
- 2014-08-31
- Completion
- 2014-08-31
Countries
- South Korea
Study Locations
More Related Trials
-
The Oral cGVHD as a Predictive Factor of Graft Versus Leukaemia Effect in Patients Who Received an Allograft
NCT07271498 ·Status: COMPLETED
-
A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-
NCT00189748 ·Status: COMPLETED ·Phase: PHASE2
-
Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide
NCT06828796 ·Status: RECRUITING ·Phase: PHASE2
-
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
NCT01244906 ·Status: COMPLETED ·Phase: PHASE2
-
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
NCT05515029 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
NCT01858740 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Treg Cell in the Treatment of GVHD
NCT06411184 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Pharmacological Predictors of Successful Cyclosporine Acute GVHD Prophylaxis in Children Undergoing HSCT
NCT02175615 ·Status: COMPLETED
-
Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation
NCT02044185 ·Status: UNKNOWN
-
Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD
NCT06364319 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
NCT00914940 ·Status: TERMINATED ·Phase: PHASE2
-
Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT
NCT02876679 ·Status: COMPLETED ·Phase: PHASE2
-
First Line Therapy for High Risk Acute GVHD
NCT04061876 ·Status: COMPLETED ·Phase: PHASE2
-
Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease
NCT01713400 ·Status: COMPLETED ·Phase: PHASE2
-
Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the HUS
NCT05618275 ·Status: UNKNOWN
-
Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia
NCT06516679 ·Status: RECRUITING ·Phase: PHASE2
-
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
NCT01789255 ·Status: COMPLETED ·Phase: PHASE2
-
Pediatric GVHD Low Risk Steroid Taper Trial
NCT05090384 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease
NCT05348096 ·Status: UNKNOWN ·Phase: PHASE2
-
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
NCT03779854 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
NCT04294641 ·Status: COMPLETED ·Phase: PHASE2
-
Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
NCT06926595 ·Status: RECRUITING ·Phase: PHASE2
-
Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)
NCT01757197 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy Study of Low-dose Glucocorticoid Prophylaxis for Acute Graft-versus-host Disease(GVHD)
NCT01607580 ·Status: COMPLETED ·Phase: NA
-
Combination of Steroid and Humanized CD25 Monoclonal Antibody as First-line Therapy for aGVHD
NCT06473909 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2